An AllTrials project

NCT04530136: A trial that was reported late by Pharming Technologies B.V.

This trial has reported, although it was 168 days late in doing so.

Full data

Full entry on NCT04530136
Title Recombinant Human C1 Esterase Inhibitor (Ruconest®) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the United States (PROTECT-COVID-19-US)
Results Status Reported (late)
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date Nov. 30, 2020
Completion date Sept. 7, 2021
Required reporting date Sept. 7, 2022, midnight
Actual reporting date Feb. 22, 2023
Date last checked at April 10, 2023
Days late 168